Correction to: Rebuttal letter on "Comment on tumor necrosis factor inhibitors prevent structural damage in hips in ankylosing spondylitis-time to reconsider treatment guidelines? A case series and review of literature".
作者信息
Rocha Francisco Airton Castro, Deodhar Atul
机构信息
Faculdade de Medicina, Department of Internal Medicine, Universidade Federal do Ceará, Fortaleza, CE, Brazil.
Laboratório de Investigação em Osteoartropatias, Instituto de Biomedicina, Rua Cel. Nunes de Melo, 1315 - 1°. Andar, Rodolfo Teófilo, Fortaleza, CE, 60430-270, Brazil.
出版信息
Clin Rheumatol. 2021 Jul;40(7):3025. doi: 10.1007/s10067-021-05741-4.
PMID:33948769
Abstract
摘要
相似文献
1
Correction to: Rebuttal letter on "Comment on tumor necrosis factor inhibitors prevent structural damage in hips in ankylosing spondylitis-time to reconsider treatment guidelines? A case series and review of literature".对《关于“对肿瘤坏死因子抑制剂预防强直性脊柱炎髋关节结构损伤——是时候重新考虑治疗指南了？病例系列及文献综述”的反驳信》的勘误
Clin Rheumatol. 2021 Jul;40(7):3025. doi: 10.1007/s10067-021-05741-4.
2
Rebuttal letter on "Comment on Tumor necrosis factor inhibitors prevent structural damage in hips in ankylosing spondylitis-time to reconsider treatment guidelines? A case series and review of literature".关于《评肿瘤坏死因子抑制剂预防强直性脊柱炎髋关节结构损伤——是时候重新考虑治疗指南了？病例系列及文献综述》的反驳信
Clin Rheumatol. 2021 May;40(5):2107-2108. doi: 10.1007/s10067-021-05705-8. Epub 2021 Mar 22.
3
Tumor necrosis factor inhibitors prevent structural damage in hips in ankylosing spondylitis-time to reconsider treatment guidelines? A case series and review of literature.肿瘤坏死因子抑制剂能否预防强直性脊柱炎髋关节结构损伤？一项病例系列研究及文献复习
Clin Rheumatol. 2021 May;40(5):1881-1887. doi: 10.1007/s10067-020-05519-0. Epub 2020 Nov 23.
4
Comment on "Tumor necrosis factor inhibitors prevent structural damage in hips in ankylosing spondylitis-time to reconsider treatment guidelines? A case series and review of literature".评《肿瘤坏死因子抑制剂可预防强直性脊柱炎患者髋关节结构损伤——是否该重新考虑治疗指南？病例系列及文献综述》
Clin Rheumatol. 2021 May;40(5):2109-2110. doi: 10.1007/s10067-021-05683-x. Epub 2021 Mar 22.
5
The Safety Profile of Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis: Are TNF Inhibitors Safer Than We Thought?肿瘤坏死因子抑制剂在强直性脊柱炎中的安全性：肿瘤坏死因子抑制剂比我们想象的更安全吗？
J Clin Pharmacol. 2019 Apr;59(4):445-462. doi: 10.1002/jcph.1348. Epub 2018 Nov 26.
6
Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis.脊柱关节炎（包括银屑病关节炎）中抗肿瘤坏死因子治疗的最新进展。
Curr Opin Rheumatol. 2006 Jul;18(4):347-53. doi: 10.1097/01.bor.0000231901.19795.8a.
7
Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years.在接受TNF-α抑制剂治疗长达10年的强直性脊柱炎患者中，尽管脊柱影像学表现有进展，但身体功能和脊柱活动度仍保持稳定。
J Rheumatol. 2016 Dec;43(12):2142-2148. doi: 10.3899/jrheum.160594. Epub 2016 Nov 1.
8
Structural damage and motion rhythm of the spine and hip during trunk lateral bending in ankylosing spondylitis patients with mild to moderate radiographic signs.轻度至中度影像学表现的强直性脊柱炎患者在躯干侧屈时脊柱和髋关节的结构损伤及运动节律
Clin Biomech (Bristol). 2019 Mar;63:112-118. doi: 10.1016/j.clinbiomech.2019.02.013. Epub 2019 Feb 23.
9
Study protocol: COmparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of StrUctural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) - an open-label randomized controlled multicenter trial.研究方案：在强直性脊柱炎患者中比较添加非甾体抗炎药的抗肿瘤坏死因子α疗法与单纯抗肿瘤坏死因子α疗法对脊柱结构损伤进展的影响，为期两年（CONSUL）——一项开放标签随机对照多中心试验。
BMJ Open. 2017 Jun 10;7(6):e014591. doi: 10.1136/bmjopen-2016-014591.
10
New therapeutic approaches for spondyloarthritis.脊柱关节炎的新治疗方法。
Curr Opin Rheumatol. 2007 May;19(3):259-64. doi: 10.1097/BOR.0b013e3280ad46a9.
Zotero 插件